Aquabounty Technologies Inc (ABTX)
market vs.
industry GROWTH & VALUE
| Trailing 12m | ||||
| PE Ratio (ttm) | n/a |
|
|
|
| PEG Ratio (ttm) |
|
|
||
| EPS Growth (ttm) | % |
|
|
|
| Dividend Yield (ttm) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | n/a |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | $m | |||||||||
| Operating Profit | $m | |||||||||
| Net Profit | $m | |||||||||
| EPS Reported | $ | |||||||||
| EPS Normalised | $ | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | $ | |||||||||
| Capex ps | $ | |||||||||
| Free Cashflow ps | $ | |||||||||
| Dividends | ||||||||||
| Dividend ps | $ | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | $m | |||||||||
| Working Capital | $m | |||||||||
| Net Fixed Assets | $m | |||||||||
| Net Debt | $m | |||||||||
| Book Value | $m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | $ | |||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Aqua Bounty Technologies, Inc. revenues was not reported. Net loss increased 63% to $4.4M. Higher net loss reflects Gain on royalty based financing instrume decrease from $2.7M (income) to $0K, Interset Expenses, Net increase from $3K to $9K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.04 to -$0.05. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: |
AquaBounty Technologies, Inc. (AquaBounty) is a biotechnology company. The Company is engaged in research and development of the commercial viability of a group of proteins, known as antifreeze proteins (AFPs). The Company focuses on improving productivity in the aquaculture market. The Company is developing advanced hybrid salmon, trout and tilapia designed to grow faster than traditional broodstock, under the name AquAdvantage. AquaBounty’s subsidiaries include AquaBounty Canada, Inc. and AquaBounty Panama, S. de R.L. AquaBounty Canada, Inc. was formed for the purpose of establishing a commercial biotechnology laboratory to produce antifreeze proteins and to conduct research and development programs related to the commercialization of cryopreservatives and the antifreeze gene construct. AquaBounty Panama, S. de R.L. was formed for purpose of conducting commercial trials of the Company’s AquAdvantage Salmon.
Directors: Ronald Stotish (CEO) 63, David Frank (CFO) , Henry Clifford (VP) ,
No. of Employees: 0 No. of Shareholders: n/a
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 102,255,688 |
| Free Float | 26.0m (25.4%) |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Suite 395,Two Clock Tower Place Maynard, WALTHAM, 01754, United States |
| Web | http://www.aquabounty.com/ |
| Phone | +1 781 8997755 |
| Contact | David Frank (Chief Financial Officer, Company Secretary) |
| Registrar | Capita IRG (Offshore) Limited |
| Auditors | Wolf & Co. |
| 18th Apr | Preliminary Results 2012 |
| 9th Apr | Exercise of Options |
| 18th Mar | Result of General Meeting |
| 15th Feb | Directorate Change |
| 13th Feb | Update on FDA Approval |
| 7th Jan | Update on proposed offer |
Recent ↓
